SLGL vs. MIST, ASMB, RLMD, PRPH, VSTM, PMVP, ORMP, SCYX, SLS, and CMRX
Should you be buying Sol-Gel Technologies stock or one of its competitors? The main competitors of Sol-Gel Technologies include Milestone Pharmaceuticals (MIST), Assembly Biosciences (ASMB), Relmada Therapeutics (RLMD), ProPhase Labs (PRPH), Verastem (VSTM), PMV Pharmaceuticals (PMVP), Oramed Pharmaceuticals (ORMP), SCYNEXIS (SCYX), SELLAS Life Sciences Group (SLS), and Chimerix (CMRX). These companies are all part of the "pharmaceutical preparations" industry.
Sol-Gel Technologies (NASDAQ:SLGL) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, profitability, valuation, earnings, community ranking, risk and dividends.
Sol-Gel Technologies received 71 more outperform votes than Milestone Pharmaceuticals when rated by MarketBeat users. However, 68.14% of users gave Milestone Pharmaceuticals an outperform vote while only 63.25% of users gave Sol-Gel Technologies an outperform vote.
In the previous week, Milestone Pharmaceuticals had 5 more articles in the media than Sol-Gel Technologies. MarketBeat recorded 5 mentions for Milestone Pharmaceuticals and 0 mentions for Sol-Gel Technologies. Milestone Pharmaceuticals' average media sentiment score of 1.18 beat Sol-Gel Technologies' score of 0.00 indicating that Milestone Pharmaceuticals is being referred to more favorably in the news media.
Sol-Gel Technologies has a beta of 1.53, indicating that its stock price is 53% more volatile than the S&P 500. Comparatively, Milestone Pharmaceuticals has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.
Sol-Gel Technologies currently has a consensus target price of $6.50, indicating a potential upside of 698.92%. Milestone Pharmaceuticals has a consensus target price of $10.75, indicating a potential upside of 636.30%. Given Sol-Gel Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe Sol-Gel Technologies is more favorable than Milestone Pharmaceuticals.
Milestone Pharmaceuticals has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -1,329.13%. Sol-Gel Technologies' return on equity of -56.20% beat Milestone Pharmaceuticals' return on equity.
26.2% of Sol-Gel Technologies shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 66.5% of Sol-Gel Technologies shares are held by company insiders. Comparatively, 10.4% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sol-Gel Technologies has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Sol-Gel Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
Sol-Gel Technologies beats Milestone Pharmaceuticals on 11 of the 19 factors compared between the two stocks.
Get Sol-Gel Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SLGL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SLGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sol-Gel Technologies Competitors List
Related Companies and Tools
